Police & Firemen s Retirement System of New Jersey Has $335,000 Position in CG Oncology, Inc. $CGON

Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 10.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 12,879 shares of the company’s stock after purchasing an additional 1,232 shares during the period. Police & Firemen s Retirement System of New Jersey’s holdings in CG Oncology were worth $335,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Millennium Management LLC lifted its position in CG Oncology by 139.4% during the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock worth $14,597,000 after buying an additional 347,055 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of CG Oncology by 11.2% in the first quarter. Wellington Management Group LLP now owns 2,125,208 shares of the company’s stock worth $52,046,000 after acquiring an additional 214,738 shares during the last quarter. Nuveen LLC bought a new position in shares of CG Oncology in the first quarter worth about $4,084,000. TD Asset Management Inc lifted its position in shares of CG Oncology by 198.5% during the second quarter. TD Asset Management Inc now owns 203,872 shares of the company’s stock worth $5,301,000 after purchasing an additional 135,566 shares in the last quarter. Finally, Woodline Partners LP grew its stake in shares of CG Oncology by 21.5% during the first quarter. Woodline Partners LP now owns 764,357 shares of the company’s stock valued at $18,719,000 after purchasing an additional 135,472 shares during the last quarter. 26.56% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on CGON shares. Cantor Fitzgerald restated an “overweight” rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Monday, September 8th. Guggenheim began coverage on CG Oncology in a research report on Tuesday, October 7th. They set a “buy” rating and a $90.00 target price for the company. Jones Trading began coverage on CG Oncology in a research note on Monday, September 8th. They set a “buy” rating and a $50.00 price target on the stock. Morgan Stanley raised their price target on CG Oncology from $56.00 to $79.00 and gave the company an “overweight” rating in a report on Wednesday, September 17th. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CG Oncology has an average rating of “Moderate Buy” and an average price target of $59.73.

CG Oncology Trading Down 1.5%

Shares of CGON opened at $44.84 on Thursday. The stock has a market cap of $3.62 billion, a P/E ratio of -21.98 and a beta of 1.32. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $45.78. The stock’s 50-day moving average price is $40.91 and its two-hundred day moving average price is $31.84.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.57). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 21.67%. The business had revenue of $1.51 million for the quarter, compared to the consensus estimate of $0.07 million. As a group, equities analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current year.

Insider Activity

In related news, Director James Mulay sold 5,903 shares of the company’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $43.99, for a total value of $259,672.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $41.43, for a total value of $41,430.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 175,359 shares of company stock worth $5,553,214 over the last three months. Company insiders own 7.40% of the company’s stock.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.